The $56,000 price tag is a rational response to an irrational insurance system, says a Berkeley Public Health economist in an opinion piece in this week’s New England Journal of Medicine.
Biogen priced its controversial Aduhelm (aducanumab), its controversial Alzheimer’s drug, at $56,000 a year because of a complicated web of policies that incentivize high prices, according to James Robinson, Ph.D., M.P.H.
In an opinion piece in this week’s New England Journal of Medicine, Robinson, who is a health economics professor at Berkeley Public Health, says that Aduhelm’s price is a window into the problems with drug pricing and payment in the U.S. He says the problems should be addressed by giving the Medicare the power to negotiate prices and by putting drugs through formal health technology assessments to establish their value
“The $56,000 price for aducanumab is a rational manufacturer response to an irrational insurance system,” Robinson wrote.
Robinson identifies three aspects of drug pricing and coverage that he says lead to high prices:
Dupixent Is Linked to a Higher Risk of Psoriasis in Patients With Atopic Dermatitis
July 8th 2025AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and psoriasis driven by Th17 inflammation. However, newer research has shown that these diseases can overlap in patients and may even share common pathways.
Read More
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Autoimmune Diseases Almost Double Mental Health Disorder Risk
July 7th 2025The prevalence of autoimmune disease patients with a mental health disorder is almost twice the number of patients without, suggesting there is a link between inflammation and conditions such as depression, anxiety disorder and bipolar disorder.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen